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Metaphase karyotype analysis of fetal cells obtained by amniocentesis or chorionic villus sampling is the current
standard for prenatal cytogenetic diagnosis, particularly for the detection of trisomy 21. We previously demonstrated
that large quantities of cell-free fetal DNA (cffDNA) are easily extracted from amniotic ﬂuid (AF). In this study,
we explored potential clinical applications of AF cffDNA by testing its ability to hybridize to DNA microarrays
for comparative genomic hybridization (CGH) analysis. cffDNA isolated from 11 male fetuses showed signiﬁcantly
increased hybridization signals on SRY and decreased signals on X-chromosome markers, compared with female
reference DNA. cffDNA isolated from six female fetuses showed the reverse when compared with male reference
DNA. cffDNA from three fetuses with trisomy 21 had increased hybridization signals on the majority of the
chromosome 21 markers, and cffDNA from a fetus with monosomy X (Turner syndrome) had decreased hybridiza-
tion signals on most X-chromosome markers, compared with euploid female reference DNA. These results indicate
that cffDNA extracted from AF can be analyzed using CGH microarrays to correctly identify fetal sex and aneu-
ploidy. This technology facilitates rapid screening of samples for whole-chromosome changes and may augment
standard karyotyping techniques by providing additional molecular information.
Deﬁnitive prenatal cytogenetic diagnosis is currently lim-
ited to metaphase karyotype analysis of cultured cells ob-
tained by amniocentesis or chorionic villus sampling. Be-
cause amniotic ﬂuid (AF) samples contain predominantly
dying cells, ∼1–2 wk are required to promote expansion
of the generally low number of viable cells for metaphase
analysis. When particular fetal genetic abnormalities are
suspected, additional aberrations—such as deletions, du-
plications or translocations—can be evaluated using FISH
analysis with speciﬁc DNA probes (Pergament 2000;
Hulten et al. 2003). Less routinely, the gene or chromo-
some in question can be targeted with PCR on DNA
extracted from cultured or uncultured amniocytes (Fred-
rickson et al. 1999). Newer molecular techniques, such
as comparative genomic hybridization (CGH) microar-
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ray analysis, have potential clinical applications for
rapid and detailed high-resolution genomic analysis of
uncultured fetal genetic material. However, experimen-
tation on primary amniocytes is not practical, because,
in normal pregnancies, only ∼10–30 ml can safely be
removed from the fetal sac, and the small numbers of
amniocytes obtained are required for the indicated cy-
togenetic testing and are therefore not available for re-
search purposes. Typically, after removal of cells from
the sample, several milliliters of AF supernatant are an-
alyzed for the levels of cell-free proteins, which can serve
as biomarkers for genetic abnormalities. The remaining
supernatant is normally discarded.
Cell-free fetal DNA (cffDNA) is a source of nucleic
acids that is readily available in the AF supernatant (Bian-
chi et al. 2001). We hypothesized that extraction, ﬂuo-
rescent labeling, hybridization, and analysis of AF
cffDNA could be used to simultaneously screen every
chromosome for aneuploidy, as well as any selected set
of genetic loci for subtle aberrations, such as gains or
deletions, on CGH microarrays. Thus, this microarray-
based approach could provide higher resolution, higher
sensitivity, andmore speciﬁc localization (within 100–200
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kb) of abnormalities in the fetal genome than the standard
metaphase karyotype obtained from cultured amniocytes,
which is generally limited to the pattern recognition of
∼450 Giemsa-stained bands. In the present feasibility
study, we aimed to detect whole-chromosome differences
between AF cffDNA samples by analysis of differential
hybridization patterns of markers on chromosomes X, Y,
and 21 in female, male, euploid, and aneuploid fetuses.
Approval for this study was obtained from the institu-
tional review boards of Tufts–NewEnglandMedical Cen-
ter andWomen and Infants’ Hospital to anonymously use
discarded AF supernatant samples and amniocytes from
the clinical cytogenetics laboratories.
Frozen residual AF supernatant samples were obtained
from 46 second-trimester pregnant women carrying eu-
ploid fetuses and 26 women carrying aneuploid fetuses
with known cytogenetic karyotypes. Residual amniocytes
for eight of the euploid samples were also obtained from
the clinical cytogenetics laboratory, after culture and rou-
tine karyotyping were complete. cffDNA was extracted
from each sample, by use of the Blood and Body Fluid
Vacuum Protocol (Qiagen), whichwasmodiﬁed for large
volumes. For each 10 ml of AF, the following were used:
1 ml of protease, 10 ml of buffer AL (Qiagen lysis
buffer), and 10 ml of 100% ethanol. The QIAvac vac-
uum manifold (Qiagen) was ﬁtted with 60 ml syringes
to accommodate the large volumes. DNA was extracted
from the cultured residual amniocytes using the “Pro-
tocol for Cultured Cells Appendix” of the Blood and
Body Fluid Spin Protocol (Qiagen). Quantitation of all
samples prior to hybridization to GenoSensor microar-
rays (Vysis) was performed using Hoechst H 33258 dye
(Molecular Probes), according to the manufacturer’s
protocol. Samples containing at least 100 ng of DNA
were selected for hybridization to arrays, including 28
total cffDNA samples (19 euploid and 9 aneuploid) and
the 8 corresponding euploid amniocyte DNA samples.
Study design, sample selection by known karyotype, and
DNA extractions were performed at Tufts–NewEngland
Medical Center. DNA samples were then sent in a
blinded fashion to Vysis for hybridization to arrays and
analysis of data without knowledge of fetal karyotype.
Formicroarray CGHanalysis, 100 ng each of AF “test”
DNA sample and normal reference DNA were labeled
with Cyanine 3-dCTP and Cyanine 5-dCTP (Perkin El-
mer), respectively, by direct incorporation methods with
the GenoSensor Random Priming DNA labeling kit (Vy-
sis). Samples were digested using DNase I to reduce the
size of the fragments to ∼200–800 bp. DNAwas puriﬁed
withMicroSpin S-200 Columns (AmershamBiosciences)
to remove unincorporated nucleotides and primers and
then was precipitated with ethanol. The quality and quan-
tity of labeled, fragmented DNA was assessed by elec-
trophoresis of a small fraction of the labeled material
on a 2% agarose gel. Next, each sample of labeled test
and reference DNA was combined with the preformu-
lated Microarray Hybridization Buffer (Vysis), was de-
natured, and was hybridized to a GenoSensor Array 300
according to the manufacturer’s protocol. After hybridi-
zation, microarrays were subjected to three 50% Forma-
mide 2# SSC washes and four 1# SSC washes to re-
move unhybridized and nonspeciﬁcally bound probe. A
cover slip with 4′,6-diamidino-2-phenylindole (DAPI)
mounting solution was then applied to each microarray.
DAPI stain was used for segmentation by the Geno-
Sensor software, while aqueous mounting solution pro-
tected ﬂuorescent signal from degradation. The Geno-
Sensor Reader (Vysis) was utilized to capture the resulting
ﬂuorescence, and the GenoSensor analysis software (Vy-
sis) was used for data acquisition, preprocessing, and
analysis.
The GenoSensor Array 300 is a genomic array with
287 targets, spotted in triplicate, which includes subte-
lomeric regions, microdeletions, and other loci of inter-
est, allowing for rapid ﬁne mapping of regions of gained
or lost DNA sequence. All samples were hybridized with
female reference DNA isolated from a normal female
donor. In early feasibility experiments, all test specimens
were also run against male reference DNA samples. In
later experiments, as techniques improved, test samples
were run against female reference DNA only to identify
male fetuses, under the assumption that samples from
female fetuses would show no sex-chromosome differ-
ences compared to euploid female reference DNA.
The GenoSensor software segmented and identiﬁed
each target by use of the blue (DAPI) image plane. Mean
intensities were measured from the green and red image
planes, background was subtracted, a mean ratio of
green/red signal was determined, and the ratios were nor-
malized. The normalized ratio for each target was cal-
culated relative to the modal DNA copy number, and
the statistical signiﬁcance of each change was reported
as a P value (Piper et al. 2002). A P value of !.01 in-
dicated a signiﬁcant difference between the copy num-
bers of a target and the modal clones. The data were
exported from GenoSensor software as Excel (Microsoft)
ﬁles, and JMP 5.0.1.2 software (SAS Institute) was used
to process and summarize the data (see table A [online
only], a tab-delimited ASCII ﬁle that can be imported
into a spreadsheet, for raw array data, and the associated
note). All data analysis was performed blindly, without
knowledge of fetal karyotype.
Data are presented for the informative 17 of 28 micro-
arrays hybridized with cffDNA extracted from AF and
for 7 of 8 microarrays hybridized with DNA extracted
from residual cultured amniocytes. Eleven cffDNA ar-
rays were uninformative, but the success of hybridization
improved during the course of the study. The karyotypes
for the 17 cffDNA samples were 46,XX (4), 46,XY (9),
47,XY,21 (2), 47,XX,21 (1), and 45,X (1). Of the
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Figure 1 Microarray data from two euploid and four aneuploid cffDNA AF samples. Data show the expected ratio differences for clones
from chromosomes X, Y, and 21, when sample genomes are compared with a normal female genome. Samples are labeled by sex and number,
followed by the karyotype of the reference DNA used for hybridization. All samples were hybridized with normal female reference DNA.
Female 1 had monosomy X (Turner syndrome). Female 2 and males 3 and 4 had trisomy 21. A subset of GenoSensor Array 300 clones (Vysis),
including markers on chromosomes 21, X, and Y, is shown for each array result. T/Rp target DNA to reference euploid DNA ratio of Cyanine
3 (test) and Cyanine 5 (reference) ﬂuorescent intensities (background corrected and normalized). Markers with increased copy numbers (11.2)
are highlighted in black, and markers with decreased copy numbers (!0.8) are highlighted in gray. Copy number changes with P values of !.01
are considered signiﬁcant and are underlined and shown in bold.
17 samples in this group, 7 had corresponding cellular
samples. Figures 1, 2, and 3 show data from all 17
cffDNA samples, representing chromosomes X, Y, and
21 for each of these microarrays. All nine samples from
euploid male fetuses had increased hybridization-signal
intensity for SRY and decreased signal intensity for X-
chromosome markers compared with female reference
DNA, represented by statistically signiﬁcant changes in
Cyanine 3 (test) and Cyanine 5 (reference) signal inten-
sity ratios ( ). Samples from all four euploid femaleP ! .01
fetuses had signiﬁcantly decreased hybridization signals
for SRY and increased hybridization signals for X chro-
mosome markers compared with male reference DNA
( ). As expected, when samples were comparedP ! .01
with reference DNA of the same sex, there was no sig-
niﬁcant difference in hybridization-signal intensity for
either the X or Y chromosome.
Figure 1 shows data from two euploid and four aneu-
ploid cffDNA samples. For all 13 euploid fetal samples
(11 others shown in ﬁgs. 2 and 3), markers on chromo-
some 21 were not signiﬁcantly different from euploid
reference DNA. However, the three fetal samples with
trisomy 21 had increased ratios of target-to-reference
intensities on most chromosome 21 markers (ﬁg. 1). The
fetal sample with monosomy X had decreased hybridi-
zation signals on seven of nine X-chromosome markers
compared with euploid female reference DNA (ﬁg. 2).
Figure 2 shows array data obtained when four euploid
cffDNA samples were hybridized separately with either
male or female reference DNA. Figure 3 shows com-
parison data from euploid samples in which both AF
cffDNA and DNA from the corresponding amniocytes
were hybridized separately to the arrays.
When the hybridization performance of cffDNA sam-
ples was compared with samples of DNA isolated from
their corresponding amniocytes, the cffDNA and cellular
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Figure 2 Comparison data for four euploid cffDNA AF samples, each hybridized separately with male and female reference DNA.
Data show the expected ratio differences for clones from chromosomes X, Y, and 21, when sample genomes are compared with both a normal
male genome and a normal female genome. Samples are labeled by sex and number, followed by the karyotype of the reference DNA used for
hybridization. A subset of GenoSensor Array 300 (Vysis) clones, including markers on chromosomes 21, X, and Y, is shown for each array
result. T/R p target DNA to reference euploid DNA ratio of ﬂuorescent intensities (background corrected and normalized). Markers with
increased copy numbers (11.2) are highlighted in black, and markers with decreased copy numbers (!0.8) are highlighted in gray. Copy number
changes with P values of !.01 are considered signiﬁcant and are underlined and shown in bold.
DNA samples were all informative for sex, but cffDNA
samples had higher clone-clone variability (noise). Noise
in the samples was assessed using the median adjacent-
clone ratio difference (MACRD) criterion, calculated by
determining the median of the absolute Cyanine 3–to–
Cyanine 5 ﬂuorescent intensity-ratio difference between
cytogenetically adjacent clones. This measure should nor-
mally be small. Currently, the “desirable” MACRD rec-
ommended by GenoSensor analysis software for a high-
quality assay is !0.065 (Vysis, unpublished data). Higher
MACRDs indicate poor-quality hybridization, since ad-
jacent clone pairs have similar ratios in the vast majority
of cases. On average, the MACRDs for DNA isolated
from amniocytes were 0.065, whereas cffDNA sam-
ples exhibited values of 0.05–0.084. AlthoughMACRDs
were higher for some cffDNA samples than for cellular
DNA, in cffDNA samples, the sensitivity of detection of
chromosome-21, -X, and -Y markers, measured by nor-
malized target/reference ratios of ﬂuorescent intensities
and P values, was similar, and quality values of array
parameters, including mean intratarget coefﬁcient of
variation and modal distribution of SD, were at or
below the acceptable cutoffs established frommultiple
sets of hybridizations done at Vysis for quality criteria
development.
Our results indicate that cffDNA extracted from AF
can be analyzed using CGH microarrays to correctly
identify fetal sex and whole-chromosome gains or losses,
such as trisomy 21 and monosomy X. To date, no other
study has utilized DNA from the cell-free fraction of AF
for prenatal molecular diagnosis. cffDNA has the ad-
vantage of being readily available from the portion of
AF that is normally discarded. Thus, it can be used in
conjunction with standard karyotyping and will not in-
terfere with the current standard of care or compromise
fetal health. In addition, it does not require the time-
Figure 3 Comparison data for seven euploid cffDNA AF samples and their corresponding amniocyte (cellular) DNA. Data show the
expected ratio differences for clones from chromosomes X, Y, and 21, when genomes from cffDNA and genomes from cellular DNA are
compared with a normal female genome. cffDNA hybridized to the arrays nearly as well as did the DNA extracted from whole cells. Samples
are labeled by sex and number, followed by the karyotype of the reference DNA used for hybridization. All samples were hybridized with
normal female reference DNA. A subset of GenoSensor Array 300 (Vysis) clones, including markers on chromosomes 21, X, and Y, is shown
for each array result. T/R p target DNA to reference euploid DNA ratio of ﬂuorescent intensities (background corrected and normalized).
Markers with increased copy numbers (11.2) are highlighted in black, and markers with decreased copy numbers (!0.8) are highlighted in gray.
Copy number changes with P values of !.01 are considered signiﬁcant and are underlined and shown in bold.
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consuming expansion of cultured cells but can be per-
formed immediately after the specimen is received, pro-
viding a more rapid diagnosis.
Microarray CGH analysis has several advantages over
traditional cytogenetic karyotyping. It is more sensitive
for the detection of small genomic changes not revealed
by standard G-banding methods, such as microdeletions
and microduplications, and can be used to screen large
panels of selected genes of interest (Pinkel et al. 1998;
Pollack et al. 1999; Veltman et al 2002; Vissers et al.
2003). Array CGH analysis also reduces subjectivity in-
herent in G-banding and provides statistical proof of the
likelihood of the presence of an abnormality in the fetus
being tested.
The potential for molecular genetic screening of fe-
tuses is large. Ultimately, this technology could be used
for genomewide screening of submicroscopic DNA copy
number changes, including rearrangements of subtelo-
meres, which are a recently recognized cause of mental
retardation (Flint et al. 1995; Knight et al. 1999; Bie-
secker 2002; deVries et al 2003). Array CGH technology
has been shown elsewhere to be robust for detection of
microdeletions and microduplications in patients with
an apparently normal metaphase karyotype, by use of
DNA from blood lymphocytes (Vissers et al. 2003). Pre-
natal array CGH analysis of AF could thus provide more
rapid and comprehensive information about the fetal
genome than is currently available from standard meta-
phase karyotyping.
The performance of cffDNA for microarray analysis
was compared with DNA isolated from cultured amnio-
cytes from some of the same fetuses, to assess hybridi-
zation efﬁciency of this novel source of fetal DNA.
cffDNA showed similar performance in hybridization to
microarrays compared with cellular DNA, but it did
have more clone-clone variability (MACRD, or noise)—
which could be due to inherent degradation of cffDNA
causing inefﬁcient labeling—making these samples less
reliable than cellular DNA.
cffDNA appears to have some different properties from
DNA from whole cells. One study demonstrated that
cell-free DNA in plasma is made up of very short frag-
ments, and 79% of cffDNA in maternal plasma is !313
bp in length (Chan et al. 2004). The size distribution of
cffDNA in AF is unknown but likely also comprises small
fragments due to apoptosis. DNA degradation is also a
potential problem because of freezer storage time. How-
ever, an earlier study showed no freezer effect on deg-
radation of cffDNA in AF, whereas cffDNA in maternal
plasma degraded by 0.6 genome equivalents/ml/month
(Lee et al. 2002). In the current study, the samples of
DNA isolated from whole cells were also frozen prior
to use, and they still hybridized well to the arrays. There-
fore, degradation from freezing is probably not a major
factor affecting performance of cffDNA.
In summary, molecular analysis of cffDNA from AF
by use of CGH microarray technology is a promising
technique that allows for rapid screening of samples for
whole-chromosome changes, including aneuploidy, and
may augment standard karyotyping techniques for pre-
natal genetic diagnosis. This technology may aid the dis-
covery and description of minor genetic aberrations, such
as microdeletions and microduplications, which will po-
tentially enhance future prenatal genetic diagnostic ap-
plications. Further investigation is warranted to explore
the clinical signiﬁcance of the detection of submicro-
scopic genetic rearrangements in the developing fetus.
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